Literature DB >> 2540269

Effects of the histamine H3-agonist (R)-alpha-methylhistamine and the antagonist thioperamide on histamine metabolism in the mouse and rat brain.

R Oishi1, Y Itoh, M Nishibori, K Saeki.   

Abstract

To study the feedback control by histamine (HA) H3-receptors on the synthesis and release of HA at nerve endings in the brain, the effects of a potent and selective H3-agonist, (R)-alpha-methylhistamine, and an H3-antagonist, thioperamide, on the pargyline-induced accumulation of tele-methylhistamine (t-MH) in the brain of mice and rats were examined in vivo. (R)-alpha-Methylhistamine dihydrochloride (6.3 mg free base/kg, i.p.) and thioperamide (2 mg/kg, i.p.), respectively, significantly decreased and increased the steady-state t-MH level in the mouse brain, whereas these compounds produced no significant changes in the HA level. When administered to mice immediately after pargyline (65 mg/kg, i.p.), (R)-alpha-methylhistamine (3.2 mg/kg, i.p.) inhibited the pargyline-induced increase in the t-MH level almost completely during the first 2 h after treatment. Thioperamide (2 mg/kg, i.p.) enhanced the pargyline-induced t-MH accumulation by approximately 70% 1 and 2 h after treatment. Lower doses of (R)-alpha-methylhistamine (1.3 mg/kg) and thioperamide (1 mg/kg) induced significant changes in the pargyline-induced t-MH accumulation in the mouse brain. In the rat, (R)-alpha-methylhistamine (3.2 mg/kg, i.p.) and thioperamide (2 mg/kg, i.p.) also affected the pargyline-induced t-MH accumulation in eight brain regions and the effects were especially marked in the cerebral cortex and amygdala. These results indicate that these compounds have potent effects on HA turnover in vivo in the brain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540269     DOI: 10.1111/j.1471-4159.1989.tb09184.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  Plenary lecture. A third histamine receptor subtype: characterisation, localisation and functions of the H3-receptor.

Authors:  J C Schwartz; J M Arrang; M Garbarg; H Pollard
Journal:  Agents Actions       Date:  1990-04

2.  In vivo release of neuronal histamine in the hypothalamus of rats measured by microdialysis.

Authors:  T Mochizuki; A Yamatodani; K Okakura; M Takemura; N Inagaki; H Wada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

3.  Histamine H3 receptor agonists decrease hypothalamic histamine levels and increase stereotypical biting in mice challenged with methamphetamine.

Authors:  Junichi Kitanaka; Nobue Kitanaka; F Scott Hall; George R Uhl; Tomohiro Tatsuta; Yoshio Morita; Koh-ichi Tanaka; Nobuyoshi Nishiyama; Motohiko Takemura
Journal:  Neurochem Res       Date:  2011-05-15       Impact factor: 3.996

4.  Histamine and Seizures : Implications for the Treatment of Epilepsy.

Authors:  H Yokoyama; K Iinuma
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

5.  H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway.

Authors:  Heather Francis; Antonio Franchitto; Yoshiyuki Ueno; Shannon Glaser; Sharon DeMorrow; Julie Venter; Eugenio Gaudio; Domenico Alvaro; Giammarco Fava; Marco Marzioni; Bradley Vaculin; Gianfranco Alpini
Journal:  Lab Invest       Date:  2007-03-05       Impact factor: 5.662

6.  Role of histamine in rodent antinociception.

Authors:  P Malmberg-Aiello; C Lamberti; C Ghelardini; A Giotti; A Bartolini
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

7.  Effects of (R)-alpha-methylhistamine and scopolamine on spatial learning in the rat assessed using a water maze.

Authors:  C P Smith; A J Hunter; G W Bennett
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

8.  Production by R-alpha-methylhistamine of a histamine H3 receptor-mediated decrease in basal vascular resistance in guinea-pigs.

Authors:  R L McLeod; S B Gertner; J A Hey
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.